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Aims Collagen degradation in atherosclerotic plaques with thin ﬁbrous caps renders them more prone to rupture. Fibro-
blast activation protein (FAP) plays a role in arthritis and tumour formation through its collagenase activity. However,




(n ¼ 9;P , 0.01)andhealthyaortae(n ¼ 8;P , 0.01)byimmunostainingandwesternblotanalyses.Fibroblastactivation
protein was also increased in thin-cap (,65 mm) vs. thick-cap (≥65 mm) human coronary ﬁbroatheromata (n ¼ 12;
P , 0.01).Fibroblastactivationproteinwasexpressedbyhumanaorticsmoothmusclecells(HASMC)asshownbycolo-
calizationonimmunoﬂuorescentaorticplaquestainings(n ¼ 10;P , 0.01)andbyﬂowcytometryincellculture.Although
macrophagesdidnotexpressFAP,macrophageburdeninhumanaorticplaquescorrelatedwithFAPexpression(n ¼ 12;
R
2¼ 0.763;P , 0.05).Enzyme-linkedimmunosorbentassaysshowedatime-anddose-dependentup-regulationofFAPin
responsetohumantumournecrosisfactora(TNFa)inHASMC(n ¼ 6;P , 0.01).Moreover,supernatantsfromperiph-
eral blood-derived macrophages induced FAP expression in cultured HASMC (n ¼ 6; P , 0.01), an effect abolished by
blocking TNFa (n ¼ 6; P , 0.01). Fibroblast activation proteinassociated with collagen-poor regions in human coronary
ﬁbrous caps and digested type I collagen and gelatin in vitro (n ¼ 6; P , 0.01). Zymography revealed that FAP-mediated
collagenase activity was neutralized by an antibody directed against the FAP catalytic domain both in HASMC (n ¼ 6;
P , 0.01) and in ﬁbrous caps of atherosclerotic plaques (n ¼ 10; P , 0.01).
Conclusion FibroblastactivationproteinexpressioninHASMCisinducedbymacrophage-derivedTNFa.Fibroblastactivationprotein
associates with thin-cap human coronary ﬁbroatheromata and contributes to type I collagen breakdown in ﬁbrous caps.
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Rupture of the ﬁbrous cap in advanced atherosclerotic plaques is a
critical trigger of acute coronary syndromes (ACS) that may lead to
myocardial infarction and sudden cardiac death. One of the key
events in promoting plaque instability is the degradation of the
ﬁbrous cap, which exposes the underlying thrombogenic plaque
core to the bloodstream, thereby causing thrombosis and sub-
sequent vessel occlusion.
1–3 Fibrous cap rupture is facilitated by
proteases which cleave type I collagen, the primary load-bearing
molecule in ﬁbrous caps, leading to ﬁbrous cap thinning and desta-
bilization.
4–7 Therefore, activated proteases, which localize to thin
ﬁbrous caps, have attracted attention as potential diagnostic and
therapeutic targets.
Candidate targets include matrix metalloproteinase (MMP)-2
and -9 and the cysteine protease cathepsin K each of which are
enhanced in both stable and unstable lesions.
8–11 Matrix
metalloproteinase-2 and cathepsin K staining reveal diffuse localiz-
ation throughout the plaque, whereas MMP-9 has been shown to
colocalize with macrophages beneath the ﬁbrous cap.
12–14
Although these proteases have shown potential as markers of
atherosclerotic plaques, their diffuse expression in all lesions
-warrant careful assessment of their targeting potential towards
clinically relevant unstable plaques. An ideal protease target
would be speciﬁc to the rupture-prone ﬁbrous cap; a site
perhaps more easily accessible by intravenously injected targeting
agents. Although MMPs and cysteine proteases have been well
characterized as protease targets, the role of serine proteases in
this context has not been investigated.
Fibroblast activation protein (FAP) is a membrane-bound, con-
stitutively active serine protease expressed by activated ﬁbro-
blasts in epithelial tumour stroma, arthritis, and wound healing,
but remains virtually undetectable in healthy tissues.
15–17
Fibroblast activation protein is an enzyme that exhibits dipeptidyl
peptidase IV activity, prolyl endopeptidase activity, and speciﬁcity
for type I collagen.
17–19 However, the role of FAP in athero-
sclerosis is unknown. The aim of this study was to characterize
FAP expression in human atherosclerosis and examine its
association with features of plaque instability. Moreover, we
sought to determine the mechanism of FAP induction, its down-
stream effects, and the capacity of a neutralizing FAP-speciﬁc
antibody.
Figure 1 Fibroblast activation protein expression is enhanced in human atherosclerotic aortic plaques. (A) Movat and ﬁbroblast activation
protein stainings show cross-sections of representative plaque-free aortae and type IV aortic atherosclerotic plaques (L, lumen; M, media; P,
atherosclerotic plaque; bar ¼ 400 mm). Dotted boxes indicate regions of interest in adjacent sections at high magniﬁcation (bar ¼ 50 mm).
(B) Western blot analysis of ﬁbroblast activation protein normalized to a-smooth muscle actin in plaque-free aortae (n ¼ 8), type II–III
plaques (n ¼ 8), and type IV–V plaques (n ¼ 7) shows a signiﬁcant increase in ﬁbroblast activation protein in advanced type IV–V plaques
by immunoblot densitometry. (C) Immunoﬂuorescent stainings in representative tissue sections of plaque-free aortae, type II–III plaque, and
type IV plaque show ﬁbroblast activation protein expression in red (DAPI in blue; bar ¼ 50 mm). (D) The graph reveals a signiﬁcant increase
in ﬁbroblast activation protein expression in type II–III aortic plaques (n ¼ 9) and in type IV–V plaques (n ¼ 12) compared with plaque-free
aortae (n ¼ 8).
C.E. Brokopp et al. 2714Methods
For the detailed Methods section, see Supplementary material online.
Characterization of atherosclerotic plaques
Biopsies of normal and plaque-bearing ascending aortae were obtained
from patients undergoing surgical aortic valve replacement secondary
to aortic stenosis [n ¼ 20, age (years): 63+14.5, body mass index:
27.8+5.4, diabetes mellitus 3/20, C-reactive protein (mg/L): 2.1+
1.8, triglycerides (mmol/L): 2.2+1.6, lactate dehydrogenase (IU/L):
218.9+37.8]. Aortic plaques were sectioned and graded according
to the American Heart Association (AHA) criteria
20,21 using Movat
pentachrome, Oil-Red-O, anti-CD68, and von Kossa staining (data
not shown). Coronary arteries were obtained from patients who
died after an acute myocardial infarction and embedded in parafﬁn
for sectioning. Collagen in coronary artery plaques was characterized
by Masson staining. Fibrous caps were identiﬁed as the collagen-rich
tissue separating the lumen and the necrotic core.
2 Plaques with a
minimum ﬁbrous cap thickness of ,65 mm were classiﬁed as
thin-cap, whereas plaques with a ﬁbrous cap thickness ≥65 mm were




Cross-sections from human ascending aortae (10 mm thickness) and
parafﬁn-embedded sections of coronary plaques (4 mm thickness)
were mounted on glass slides. Tissue sections were labelled against
FAP and cell-speciﬁc markers with purchased antibodies directed
against CD68, von Willebrand factor (vWF), a-smooth muscle actin
(aSMA), or type I collagen and visualization with either ﬂuorescence-
labelled secondary antibodies or biotin-labelled secondaries for immu-
nostaining using an ABC staining kit for diaminobenzidine (Vector Labs,
Burlingame, CA, USA).
Image analysis
For low-power imaging at spatial resolutions above 1 mm/pixel, a ﬂuor-
escent microscope (DM60000B; Leica, Wetzlar, Germany) equipped
with a ﬂuorescent camera (DFC350 FX; Leica) was used. Colocaliza-
tion analyses were performed at higher magniﬁcations using a multi-
channel confocal microscope (TCS SP2; Leica) on a single optical
plane.
Cells
Human aortic endothelial cells (HAEC) were isolated from biopsies of
ascending aortae without macroscopic lesions obtained from patients
undergoing operations for valve repair, human aortic smooth muscle
cells (HASMC) were purchased (Promocell), and peripheral blood-
derived monocytes were isolated from healthy subjects. Foam cells
were generated by stimulating macrophages with 100 mg/mL of oxi-
dized LDL (BT-910; BioConcept, Allschwil, Switzerland) for 48 h in
serum-free macrophage medium (SFM; Gibco). Lipid uptake was
assessed by Oil-red-O staining (O0624; Sigma-Aldrich).
Figure 2 Fibroblast activation protein expression in human aortic plaques colocalizes with smooth muscle cells, but not with macrophages or
endothelial cells. (A) Overlays of confocal images of ﬁbroblast activation protein (red) and DAPI (blue) with cell-speciﬁc stainings of a-smooth
muscle actin, CD68, and von Willebrand factor (green) in representative sections illustrate ﬁbroblast activation protein colocalization (arrows)
with smooth muscle cells (bar ¼ 20 mm). (B) The graph quantiﬁes an increased colocalization of ﬁbroblast activation protein with smooth
muscle cells (a-smooth muscle actin), compared with endothelial cells (von Willebrand factor) and macrophages (CD68) in type IV–V athero-
sclerotic plaques (n ¼ 10).
FAP in atherosclerosis 2715Fibroblast activation protein induction assays
Quiescent HASMC were treated with starvation media supplemented
with 3, 5, 10, 20, and 40% macrophage-conditioned SFM for 48 h. To
determine the effects of tumour necrosis factor a (TNFa) on FAP
expression, quiescent HASMC were treated with starvation media
supplemented with 20% macrophage-conditioned SFM and a TNFa-
neutralizing antibody (Ab6671; Abcam) or an IgG isotype control
(Ab27478; Abcam) antibody. Recombinant human TNFa (300-01A;
Peprotech) was used to induce FAP expression in quiescent HASMC
in a dose- and time-dependent manner. Fibroblast activation protein
levels were quantiﬁed by cell membrane enzyme-linked immunosor-
bent assay (see Supplementary material online, Figure S1).
Fibroblast activation protein-mediated type I
collagen degradation assays
In situ zymography was performed on 5 mm cryosections of human
aortic atherosclerotic plaques, which had been stained for FAP using
a non-inhibitory antibody (F19). Sections were then incubated with
an inhibitory antibody (A246) or isotype control (50 nM) overnight
at 48C. Subsequently, sections were mounted in warm 1% Agarose
in phosphate-buffered saline (PBS) supplemented with 10% direct-
quenched type I collagen from bovine skin (D12060; Invitrogen) and
imaged after 2 h at 378C using confocal microscopy. Image Quantiﬁ-
cation was performed as described in the Supplemental material
online.
To evaluate the FAP-mediated type I collagen-speciﬁc cleavage, full-
length native human type I collagen isolated from human placenta
(purity . 90%) was used (288; Yo Proteins). Type I collagen
(100 ng/mL) was treated with recombinant human FAP (rhuFAP;
200 nM) for 18 h at 378C in PBS (pH ¼ 7.2) and compared with an
untreated collagen control. A246 (50 ng/mL) was added to the sol-
ution and compared with an isotype control antibody IgG (Ab27478;
Abcam) to validate the neutralizing capacity of A246. Samples were
separated by electrophoresis and visualized by silver staining (Proteo-
Silver Silver Stain Kit, Sigma).
Statistical analyses
Histological and cell culture results were compared using one-way
ANOVA and associations calculated by Pearson’s correlation coefﬁ-
cient. Student’s t-test was used for comparisons of zymography. All
statistical analyses were performed using MatLab (Version, R2007b).
Data are presented as mean+SD. Signiﬁcance was accepted at the
level of P , 0.05.
Results
Fibroblast activation protein is expressed
by smooth muscle cells, but not
macrophages in advanced human
aortic plaques
Immunoﬂuorescent stainings for FAP in adjacent cryosections
revealed enhanced expression of FAP in ﬁbroatheromata vs.
plaque-free aortae (Figure 1A). Positive staining for FAP was vir-
tually absent in healthy ascending aortae, whereas a step-wise
increase was observed in type II–III and type IV–V plaques by
western blot analyses (Figure 1B; see Supplementary material
online, Figure S2) and quantitative image analysis (Figure 1C and D).
To characterize FAP-expressing cell types in human athero-
sclerotic plaques, we performed immunoﬂuorescent co-stainings
of FAP in macrophages (identiﬁed as CD68-positive cells),
smooth muscle cells (aSMA-positive cells), and endothelial cells
Figure 3 Fibroblast activation protein is constitutively
expressed in cultured human aortic smooth muscle cells
(HASMC) and human aortic endothelial cells (HAEC), but not
in peripheral blood-derived monocytes (PBM), macrophages
(MF), or foam cells. FACS analyses and Oil-Red-O staining of
peripheral blood derived-macrophages laden with oxidized LDL
characterize cells populations (left) and their respective ﬁbroblast
activation protein expression (right).
C.E. Brokopp et al. 2716(vWF-positive cells) (Figure 2A). Confocal image analyses revealed
that FAP expression by smooth muscle cells, but not by macro-
phages or endothelial cells (Figure 2B).
To validate FAP expression by vascular cells in vitro, we per-
formed FACS analyses of FAP in HASMC (aSMA-positive cells),
HAEC (vWF-positive cells), peripheral blood-derived monocytes
(CD64-positive), macrophages (CD68-positive), and foam cells
(Oil-Red-O-positive macrophages). FACS analyses revealed high
constitutive FAP expression in HASMC and slight expression in
HAEC, but no expression by peripheral blood-derived monocytes,
macrophages, or foam cells (Figure 3).
Fibroblast activation protein expression is
enhanced in thin-cap vs. thick-cap human
coronary atheromata
In order to determine the association of FAP with coronary ﬁbrous
cap thickness, we stained collagen applying the Masson method
(stains collagen in blue) in rupture-prone human coronary arteries
obtained from patients who died after myocardial infarction. On
the basis of ﬁbrous cap thickness, these specimens were character-
ized as thin-cap (,65 mm) or thick-cap (≥65 mm) ﬁbroathero-
mata. Immunohistological and immunoﬂuorescent stainings and
subsequent confocal image analyses in adjacent sections revealed
enhanced FAP expression in thin compared with thick ﬁbrous
caps (Figure 4A and B).
Fibroblast activation protein expression
associates with the macrophage burden in
human aortic atherosclerotic plaques
Immunoﬂuorescence stainings revealed FAP expression in medial
cells adjacent to macrophages in aortic fatty streaks (Figure 5A).
To characterize the relationship between FAP and inﬂammation,
we compared FAP and macrophage immunoﬂuorescent signal
intensity in human aortic plaques (Figure 5B). We observed a posi-
tive correlation between macrophage burden and FAP expression
with plaque progression (R
2¼ 0.763; n ¼ 12; Figure 5C).
Macrophage-derived tumour necrosis
factor a induces fibroblast activation
protein expression in cultured human
aortic smooth muscle cells
To elucidate a signalling mechanism between macrophages and
FAP-expressing HASMC, we exposed HASMC to macrophage-
conditioned media for 48 h to simulate conditions applicable to
plaque inﬂammation. Cultured HASMC showed a dose-
Figure 4 Fibroblast activation protein expression is enhanced in thin-cap vs. thick-cap human coronary ﬁbroatheromata. (A) Masson staining
shows collagen-rich thick (658 mm) vs. thin (45 mm) ﬁbrous caps (L, lumen; FC, ﬁbrous cap; NC, necrotic core; bar ¼ 1 mm). Fibroblast acti-
vation protein immunohistochemistry and immunoﬂuorescence (intensity scale; bar ¼ 50 mm) shows ﬁbroblast activation protein expression in
representative thin vs. thick caps. Dotted boxes indicate regions of interest in adjacent sections at high magniﬁcation. (B) The graph reveals a
signiﬁcant increase in ﬁbroblast activation protein expression in thin vs. thick ﬁbrous caps (n ¼ 12 each).
FAP in atherosclerosis 2717dependent increase in FAP expression in response to the
macrophage-conditioned media with a maximal effect observed
at 20% media concentration (Figure 6A) after 48 h. This effect
was abolished when macrophage-conditioned media was sup-
plemented with a TNFa-neutralizing antibody (Figure 6B). To
conﬁrm this paracrine effect of TNFa on FAP expression,
experiments were repeated using recombinant human
TNFa.T u m o u rn e c r o s i sf a c t o ra-mediated FAP expression
was observed in a dose- and time-dependent manner, with a
maximum response at 30 ng/mL after 48 h (Figure 6C and D).
Figure 5 Fibroblast activation protein expression correlates with macrophage burden in human aortic plaques. (A) Confocal immunoﬂuor-
escent photomicrograph of an aortic fatty streak reveals ﬁbroblast activation protein expression (red) adjacent to macrophages (CD68; green)
at low (phase-contrast, white; bar ¼ 100 mm) and high magniﬁcation (bar ¼ 25 mm). (B) Movat staining (bar ¼ 400 mm), ﬁbroblast activation
protein, or macrophage (CD68) immunoﬂuorescent stainings in plaque-free aortae, type II, and type V atherosclerotic plaques show enhanced
ﬁbroblast activation protein expression with increasing macrophage burden (bar ¼ 50 mm). (C) Comparisons of ﬁbroblast activation protein
and macrophage expression in serial adjacent sections from aortic plaques demonstrate a signiﬁcant positive correlation (R
2¼ 0.763;
n ¼ 12; P , 0.05); AU, arbitrary units.
C.E. Brokopp et al. 2718Fibroblast activation protein-mediated
type I collagenase activity in aortic ﬁbrous
caps is inhibited by a fibroblast activation
protein-neutralizing antibody
Immunoﬂuorescence analyses revealed enhanced FAP expression
in type I collagen-poor regions of aortic ﬁbrous caps (Figure 7A).
Aortic ﬁbrous caps treated with an IgG control antibody showed
a colocalization of FAP with cleaved DQ type I collagen,
whereas Ab246-treated plaques demonstrated a signiﬁcantly
reduced colocalization of FAP with type I collagenase activity
(Figure 7B). Confocal image analyses revealed that A246-treated
ﬁbrous caps exhibited decreased cleaved type I collagen at sites
of FAP expression (Figure 7C). Type I collagenase activity of
rhuFAP and the neutralizing capacity of A246 were demonstrated
by incubation of native human type I collagen with rhuFAP in the
presence of inhibiting antibody or isotype control (Figure 7D).
Discussion
The ﬁbrous cap of an atherosclerotic plaque is essential for separ-
ating the bloodstream in the vessel lumen from its thrombogenic
necrotic core. The mechanical strength of the ﬁbrous cap is pro-
vided primarily by type I collagen, which is degraded by MMPs
and cysteine proteases, both of which are associated with plaque
instability and the occurrence of acute thrombotic events.
22–26
This study links the constitutively active serine protease FAP to
plaque progression and ﬁbrous cap thinning and provides evidence
that (i) FAP expression is enhanced in human aortic atheromata
and in ﬁbrous caps of thin-cap coronary plaques, (ii) FAP is
expressed in HASMC and its expression correlates with macro-
phage burden, (iii) FAP expression is induced in HASMC by
macrophage-derived TNFa via paracrine signalling, (iv) FAP
cleaves collagen in ﬁbrous caps of human atheromata, and (v)
FAP-mediated type I collagenase activity is inhibited by an
FAP-neutralizing antibody.
Numerous studies implicate matrix-degrading collagenases such
as MMP-1, -2, and -9 as well as cysteine proteases such as cathep-
sins S and K in vascular remodelling and plaque rupture.
13,23,27 Our
ﬁndings provide evidence that FAP is the ﬁrst known smooth
muscle cell-derived serine protease involved in collagen degra-
dation in human atherosclerosis. Fibroblast activation protein
expression was particularly enhanced in ﬁbrous caps of thin-cap
Figure 6 Macrophage-derived tumour necrosis factor a induces ﬁbroblast activation protein expression in human aortic smooth muscle cells.
(A) Macrophage-conditioned supernatant induces ﬁbroblast activation protein in human aortic smooth muscle cells in a concentration-
dependent manner following 48 h exposure (n ¼ 6). (B) Using the same macrophage-conditioned medium, tumour necrosis factor a-blocking
antibody (Ab6671) decreases ﬁbroblast activation protein expression by 40% in human aortic smooth muscle cells compared with an isotype
control antibody (n ¼ 6). (C) Recombinant human tumour necrosis factor a induces ﬁbroblast activation protein in human aortic smooth
muscle cells in a dose-dependent manner after 48 h incubation (n ¼ 6). (D) Recombinant human tumour necrosis factor a induces ﬁbroblast
activation protein in human aortic smooth muscle cells in a time-dependent manner (30 ng/mL). AU, arbitrary units (*P , 0.05, **P , 0.01).
FAP in atherosclerosis 2719Figure 7 Type I collagenase activity is inhibited in human aortic ﬁbrous caps by the ﬁbroblast activation protein-blocking antibody A246. (A)
Movat staining of a ﬁbrous cap in human aortic plaque. The region of interest (black box) is shown at higher magniﬁcation in an adjacent section
stained for ﬁbroblast activation protein (red), type I collagen (green), and overlay (DAPI ¼ blue; bar ¼ 150 mm). (B) Confocal images of in situ
zymography show ﬁbroblast activation protein (red) and cleaved DQ type I collagen (green) in ﬁbrous caps shown by Movat (A) of aortic plaque
treated with a control IgG antibody or neutralizing antibody A246 (bar ¼ 10 mm). (C) The graph reveals a signiﬁcant reduction of cleaved type I
collagen colocalized with ﬁbroblast activation protein expression by in situ zymography (n ¼ 10/group). (D) Type I collagenase activity of recom-
binant human ﬁbroblast activation protein and the neutralizing capacity of A246 was demonstrated by incubation of native human type I collagen
with recombinant human ﬁbroblast activation protein in the presence of inhibiting or isotype control antibodies (lanes: 1, rhuFAP; 2, collagen; 3,
rhuFAP + collagen; 4, rhuFAP + collagen + A246; 5, rhuFAP + collagen + isotype control antibody; 6, molecular weight marker).
C.E. Brokopp et al. 2720human coronary plaques isolated from patients who died after
myocardial infarction. Indeed, thin ﬁbrous caps (,65 mm) have
been associated with sudden cardiac death.
2,28 The type I collagen-
ase activity of FAP is demonstrated by both FAP-mediated collage-
nolysis in ﬁbrous caps and the association of FAP with
collagen-poor ﬁbrous cap tissue in image analyses. These obser-
vations underline the potential clinical relevance of FAP as a diag-
nostic and/or therapeutic target in patients with plaques prone to
rupture, i.e. patients at risk for ACS or stroke.
Inﬂammation constitutes a key feature of plaque vulnerability
and inﬂammatory processes have been shown to induce collagen-
ases in atherosclerotic plaques.
4,29,30 Consistent with this para-
digm, we demonstrate that FAP expression in HASMC is
associated with macrophage burden in intermediate and advanced
human atherosclerotic plaques. Fibroblast activation protein was
not expressed by macrophages. However, macrophage-derived
TNFa induced a dose- and time-dependent increase in FAP
expression in cultured smooth muscle cells. These data indicate
that a paracrine inﬂammatory pathway can induce FAP expression
in smooth muscle cells. Thereby, our ﬁndings contribute to a
growing body of evidence that supports the notion of
inﬂammation-induced collagenase expression in atherosclero-
sis.
6,11,22,31 Such ﬁndings could motivate future studies to investi-
gate putative atheroprotective interventions involving either key
anti-inﬂammatory mechanisms, such as the TNFa pathway,
collagen-degrading enzymes themselves such as FAP, or both.
In addition to its expression in smooth muscle cells, we detected
constitutive FAP expression in HAEC in vitro. Endothelial activation
is a critical step in atherogenesis.
32 Activated endothelial cells
express ﬁbrous cap-degrading collagenases and have also been
shown to act in concert with ﬁbrous cap-degrading smooth
muscle cells.
5,25,33 Indeed, the observed capacity of endothelial
cells to express FAP in vitro supports the notion of a coordinated
remodelling of the ﬁbrous cap by both endothelial and smooth
muscle cells. Furthermore, by recruiting blood-borne inﬂammatory
cells to the plaque, activated endothelial cells may also enhance
macrophage-derived cytokine release, activate smooth muscle
cells, and thus induce FAP expression and/or activity.
Distinct from MMPs, FAP combines several unique properties:
MMPs exhibit diffuse expression throughout both intermediate
and advanced atherosclerotic plaques.
14 In contrast, FAP
expression is associated speciﬁcally with thin-cap atheromata.
Moreover, MMP activity is modiﬁed by tissue inhibitors of metallo-
proteinases, whereas no natural inhibitors of the constitutively
active FAP are identiﬁed. It is therefore plausible that FAP
expression associates with its activity, rendering FAP a potential
diagnostic target. Furthermore, we demonstrate that FAP is
mainly expressed in activated smooth muscle cells in thin ﬁbrous
caps of advanced atherosclerotic plaques. Given its localization in
the ﬁbrous cap close to the bloodstream, FAP may be more acces-
sible than MMPs by circulating targeting agents.
34
Taken together, we found that FAP expression is induced by
macrophage-derived TNFa in HASMC, associates with thin-cap
human coronary plaques, and contributes to type I collagen break-
down in ﬁbrous caps. Thus, FAP expression in thin-cap coronary
plaques and endothelial cells renders this target attractive for
further investigation in patients with ACS. Along this line, we
plan to investigate whether soluble FAP may be a biomarker for
ACS. Moreover, our present ﬁndings demonstrate that FAP-
mediated collagenolysis is induced by inﬂammatory cues and may
be blocked by neutralizing antibodies. At the experimental level,
studies using genetic or pharmacological modulation of FAP will
shed light onto the causal role of FAP in atherogenesis and its
potential use as a target in atherosclerosis and other inﬂammatory
diseases such as rheumatoid arthritis and tumour formation.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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